Background Generic drugs offer a less expensive and therapeutically equivalent alternative to brand name drugs. Nevertheless, many Canadian private drug plans continue to pay for brand name drugs even after generics become available. Objective The objective of this study was to quantify the excess spending resulting from this practice. Methods We used the IMS Brogan PharmaStat database to study private-plan drug spending in Ontario from 2000 to 2009. We focused on three widely used drug classes: proton pump inhibitors (PPIs), selective serotonin reuptake inhibitors (SSRIs), and angiotensin-converting enzyme (ACE) inhibitors. For each specific molecule, we determined the difference between what private plans spent on the brand name version and what would have been spent if an available generic version of the same molecule had been purchased instead. Results We found that prescriptions paid for by private drug plans were often filled with brand name drugs after generics became available. This led to excess private spending of more than Can$107.8 million for these three drug classes over our study period: Can$54.4 million for PPIs, Can$32.4 million for SSRIs and Can$21.0 million for ACE inhibitors. Interpretation Brand name drugs continue to be reimbursed by Canadian private drug plans at higher prices even after less expensive generic alternatives are available. By mandating generic substitution, substantial cost savings on benefit plans could be achieved.
Introduction
Prescription drugs account for more than 15 % of healthcare spending in Canada (by both public and private payers), amounting to approximately Can$30 billion per year (all monetary values are in Canadian dollars) [1] . One way to reduce these expenditures is through the use of generic drugs, which are sold at a reduced price to both public and private payers. In Canada, generic drugs are typically regulated through price caps set as a percentage of the equivalent brand name medicine. These prices are typically extended to all plans, including those run by private insurers [2] . Generic drug manufacturers must demonstrate bioequivalence before they can obtain permission to sell their products in Canada. Clinical studies have also shown that generic drugs are therapeutically equivalent to their branded counterparts, meaning payers could achieve substantial savings by purchasing generics when they are available [3] [4] [5] . Depending on the province, about 50-60 % of prescriptions are for generic drugs, while the rest are for exclusive or brand name drugs [3] . Recently, several frequently prescribed medications, such as atorvastatin and clopidogrel, have become available as generics, meaning that the potential savings from substitution policies is increasing [6] . Although each province in Canada operates a public drug programme, these programmes are not universal. As a result, private insurance is the primary source of prescription drug coverage for approximately 60 % of Canadians [7] . The strategies employed to increase the use of generic alternatives vary between public and private drug plans in Canada. In the public sector, every province encourages the use of generic drugs by limiting reimbursement for brand name drugs with available generic equivalents. In contrast, generic substitution is not mandated by all private plans in Canada. As a result, the proportion of prescriptions filled using generic drugs is substantially lower in private than in public drug programmes. One private benefits claims manager, ESI Canada, found that 51 % of private claims were for generic drugs [8] , compared with a rate of over 60 % for drug sales in Canada as a whole [9] .
The excess spending due to the continued use of brand name prescription drugs (also known as originator molecules) when generics are available in private plans is unknown. The situation in Canada is unclear, as in the past, pharmacies have had strong financial incentives to dispense generics [10] . Improving efficiency in the private insurance market is an important public policy objective, because the excess money spent on brand name drugs could instead be used to increase personal income, increase corporate profits or lower insurance premiums. As employer-paid premiums are tax-exempt federally in Canada, this could lead to increased tax revenues. We therefore studied the potential savings to private payers for three popular classes of prescription drugs: proton pump inhibitors (PPIs), selective serotonin reuptake inhibitors (SSRIs) and angiotensinconverting enzyme (ACE) inhibitors.
Methods

Data Sources
Our study used Ontario data from the IMS Brogan PharmaStat database, which has an 87% capture rate for private drug claims in Ontario. Prescriptions paid for out of pocket are not included in this database. IMS Brogan databases are considered to be reliable indicators of drug utilization and spending and are widely used by researchers [11, 12] . We chose to focus on Ontario, the largest province in Canada [1] , because public drug plan formularies vary from one province to another.
Drug Classes
We considered three of the most commonly dispensed categories of prescription drugs on a long-term basis: PPIs, which are most frequently prescribed for gastroeosophageal reflux, ACE inhibitors, which are most frequently prescribed for hypertension, and SSRIs, which are most frequently prescribed for depression and anxiety. We chose these three drug classes because they are collectively used to treat a diverse group of diseases, they are widely prescribed and in each category there are several products with available generics that have been proven to be bioequivalent to their brand name counterparts.
The PharmaStat database includes all PPI, ACE inhibitor, and SSRI molecules (brand name and generic) that were reimbursed in Ontario by private plans between 1 January 2000 and 31 December 2009 (Table 1) . For each drug, we examined generic and brand name expenditures, as well as the number of generic and brand name 'units' (e.g. the number of pills or capsules) sold for each year under study.
Analysis
To determine the excess private spending resulting from paying for brand name drugs after generics were available, we used the first instance of a generic sale to indicate the date of generic entry. As our data were aggregated to the yearly level, we excluded from our calculations the first full year in which the generic became available (unless it was already available in 2000), as we could not determine what proportion of branded product was dispensed after the generic was first marketed. For example, if a generic version of the medication was first sold in 2005, our determination of excess spending would only include sales data from 2006 onward. Excess spending was determined using only generic drugs with chemically identical active ingredients (e.g. spending on Pantoloc Ò after the introduction of generic pantoprazole), not at the class level (e.g. spending on Pantoloc Ò after the introduction of generic omeprazole). This was done on a yearly basis by calculating how much would have been spent if all units of a particular molecule sold that year had been generic (using the unit cost of that particular generic drug in that particular year) and subtracting that from the actual amount that was spent on all versions of that molecule (generic and brand name) in that particular year. This calculation was done separately for each year that the generic molecule was available, as explained above, in order to arrive at the overall excess spending. Costs were not adjusted to a common year.
Results
Overall
The additional total cost incurred for the three medication groups over the period of study was Can$107.8 million for private drug plans (Table 2 ). This represented 4.0 % of the total spending by private drug plans in Ontario, approximately Can$2. (Fig. 3) . Generic SSRIs have been available since before the year 2000. The number of SSRI units sold to patients has been increasing (41.9 million SSRI units were sold in 2000; this number increased to 79.9 million by 2009). Meanwhile, in the period under study, the expenditures originally increased, but then decreased, before starting to steadily rise again in recent years. Examining the utilization trends for specific molecules, the only brand name SSRI that was still used to any significant extent in 2009 was Cipralex Ò (escitalopram), which first became available in 2005 for those with private Meanwhile, the total cost of ACE inhibitors has decreased.
Interpretation
Because generic drugs are bioequivalent to brand name drugs yet substantially cheaper, their availability offers an opportunity for savings for both public and private payers. We found that private payers continue to pay large amounts for brand name drugs even after generics enter the market.
For the three drug classes we studied (PPIs, SSRIs and ACE inhibitors), the excess private expenditure in Ontario was more than Can$117 million-or 4. Some patients and physicians are reluctant to switch from brand name to generic drugs, despite proven equivalence and efficacy. Reference-based pricing, a system in which the third-party payer only pays for the cheapest molecule (or drug, where two or more drugs are viewed as being therapeutically equivalent), provides a financial disincentive to patients who wish to continue to be treated with a brand name drug even after a generic version is available [13] [14] [15] . Although reference-based pricing is common among public sector payers in Canada, many private insurance plans continue to pay a higher price for brand name drugs even after generics enter the market.
Our study has several limitations. Our study methodology does not allow us to ascertain why brand name products were being purchased instead of available generics. Further, our estimates do not account for the lower generic price caps for private payers introduced in Ontario in 2010 [2] . However, these price reductions would only act to make our results a conservative estimate of potential savings to private plans.
The entry of generic versions of a medicine results in savings for private and public payers. However, our results indicate these savings are not fully realized by private payers because many branded drugs are still purchased even after generics become available. This excess spending could otherwise benefit employees and their companies through higher salaries, lower insurance premiums and increased profits for shareholders. The potential savings are likely even greater now than in our study period, as the price of generics dropped dramatically in Ontario in 2010 [2] . One possible explanation for the lack of use of generics is the low rate of mandatory generic substitution policies in many private drug plans. It is worth noting that intermediaries in the private insurance market (e.g. wholesalers and distributors), and sometimes the private insurance companies themselves, benefit from paying for brand name drugs even when cheaper generics are available. For example, administrative charges are typically assessed as a percentage of expenditure, so higher-priced drugs result in greater revenues than cheaper drugs. Important policy learning for private plans is likely to be found in public plans in Canada. For example, every public drug plan in Canada requires generics to be used when they are available [3] .
Overall, the market entry of generic versions of a medicine results in savings for Canadian drug plans. However, our results indicate these substantial savings are not fully realized by private drug plans because many branded drugs are still purchased when new generic drugs become available. Canadian employers, as well as employees and their representatives, should consider using plan design to encourage the use of generic drugs by their employees in order to slow the ever-increasing cost of their drug benefits plans.
